Last reviewed · How we verify
NCT04843371
Photoplethysmography (PPG) to Predict Ejection Fraction and Other Echographic Data in the General Population
trial testing Photoplethysmography in Valvular Heart Disease in 500 participants. Currently enrolling.
1 December 2026
Quick facts
| Lead sponsor | Tulane University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 20 August 2021 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Photoplethysmography
Conditions studied
- Valvular Heart Disease — all drugs for Valvular Heart Disease →
- Pericardial Disease — all drugs for Pericardial Disease →
- Cardiomyopathies — all drugs for Cardiomyopathies →
Sponsor
Tulane University
Who can join
Adults 18 to 120, any sex, with Valvular Heart Disease or Pericardial Disease. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Association between obtained PPG waveforms and recorded ejection (EF) fractions.
Time frame: Day 1
Patients who will undergo echocardiogram will wear the biostrap watch and then the PPG waveform will be obtained. Then, the ejection fraction will be collected from the echocardiogram report. Then, the Artificial Intelligence (AI) staff member will do a predictive model to try and estimate the EF based on the PPG waveform.
Sponsor's own description
The investigators are aiming to investigate the association between ejection fraction (EF) determined by echocardiography and signals obtained from Photoplethysmography (PPG) in the general population. The investigators are also aiming to investigate the association between blood pressure and signals obtained from PPG in the general population. Finally, the investigators are also aiming to investigate the association between signals obtained from PPG in the general population to cardioechographic findings such as, valvular heart disease, structural heart diseases, cardiomyopathies, pericardial disease etc.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04843371
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Photoplethysmography
Trials testing the same drug.
- NCT06154642 — Perioperative Hemodynamic and Microcirculatory Physiological Study During TAVI · completed
- NCT06305884 — Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study · NA · completed
- NCT04549194 — Contribution of L-Tyrosine to Recovery From Operational Strain on Return From External Operation · NA · completed
Other recruiting trials for Valvular Heart Disease
Currently open trials in the same condition.
- NCT07197736 — DELINEATE-Prospective · recruiting
- NCT07042529 — Optimized Expansion of the Implanted Transcatheter Aortic Valve · NA · recruiting
- NCT07065500 — Mechanism and Effect of Novel Metabolites on Valvular Heart Disease · recruiting
- NCT07099417 — Screening of Valvular Heart Disease Using Single-channel Electrocardiogram · recruiting
- NCT06386016 — Detection of Valvular Heart Disease Using Artificial Intelligence-based Stethoscope · recruiting
Other Tulane University trials
Trials by the same sponsor.
- NCT04007276 — The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients · Phase 4 · not yet recruiting
- NCT07062406 — Enhancing Diabetes Care by Treating Insomnia · NA · not yet recruiting
- NCT06810739 — The Women's Screening and Self-Testing Program (PROMETA) Study · NA · not yet recruiting
- NCT05197998 — Promoting ColorBRAVE Conversations in Families · NA · suspended
- NCT06261840 — Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04843371 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tulane University
- Last refreshed: 3 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04843371.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing